Tag: AML

NuProbe Technology Showcases Quantitative PCR for

Houston, January 18, 2022 (GLOBE NEWSWIRE) – NuProbe, a genomics and molecular diagnostics company that develops ultra-sensitive tests for precision cancer research, today released research demonstrating new technology to qualitatively and quantitatively detect multiple low-grade variants frequency in a quantitative PCR (qPCR reaction). The new allele-specific BDA technology (As-BDA) uses…

Continue Reading NuProbe Technology Showcases Quantitative PCR for

Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence

Materials and Methods Genomic data was collected as part of the MDS National History Study or The Cancer Genome Atlas project and consented appropriately under those protocols 8 Sekeres M.A. Gore S.D. Stablein D.M. DiFronzo N. Abel G.A. DeZern A.E. Troy J.D. Rollison D.E. Thomas J.W. Waclawiw M.A. Liu J.J….

Continue Reading Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence

h2o.explain function – RDocumentation

Description The H2O Explainability Interface is a convenient wrapper to a number of explainabilty methods and visualizations in H2O. The function can be applied to a single model or group of models and returns a list of explanations, which are individual units of explanation such as a partial dependence plot…

Continue Reading h2o.explain function – RDocumentation

Celyad Oncology Presents Updates on shRNA-Based CAR T

Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programs Management to host conference call today December 13th at 2:30 p.m. CET / 8:30 a.m. EST MONT-SAINT-GUIBERT, Belgium, Dec. 13, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext &…

Continue Reading Celyad Oncology Presents Updates on shRNA-Based CAR T

PyTorch model conversion – Technical Support

I’m unable to convert a model in pytorch This is the script to download the pretrained weights import torch import torchvision.models as models resnet18 = models.resnet18(pretrained=True) torch.save(resnet18, ‘resnet18.pt’) This is the script for converting ./convert –model-name resnet18 –platform pytorch –model resnet18.pt –input-size-list ‘3,224,224’ –mean-values ‘103.94,116.78,123.68,58.82’ –quantized-dtype asymmetric_affine –kboard VIM3 –print-level…

Continue Reading PyTorch model conversion – Technical Support

Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

– QIAGEN’s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo’s new investigational cancer treatment DB102 – The partners seek FDA premarket approval (PMA) of the companion diagnostic test in tandem with the new drug application (NDA) approval. SAN DIEGO and…

Continue Reading Denovo Biopharma and QIAGEN partner to develop companion diagnostic test for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Oral and Poster Abstracts 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III Translational Research Maher Albitar, MD1*, Andrew Ip, MD, MSc2, Andre H. Goy, MD3*, Jeffrey Justin Estella, BS, MS1*, Ivan De Dios, BS1*,…

Continue Reading Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

QIAGEN’s blood-based test will help to identify patients with Diffuse Large B-Cell Lymphoma (DLBCL) likely to respond to Denovo’s new investigational cancer treatment DB102TM The partners seek FDA premarket approval (PMA) of the companion diagnostic test in tandem with the new drug application (NDA) approval. New master collaboration agreement adds…

Continue Reading QIAGEN and Denovo Biopharma Partner to Develop Companion Diagnostic Test for the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)

Non-genetic determinants of malignant clonal fitness at single-cell resolution

1. Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 20, 404–416 (2019). CAS  PubMed  Google Scholar  2. Marine, J. C., Dawson, S. J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743–756 (2020). CAS …

Continue Reading Non-genetic determinants of malignant clonal fitness at single-cell resolution

MD Anderson research highlights 9 December

ATLANTA ― The University of Texas MD Anderson Cancer Center‘s Research Highlights provides a glimpse into basic, translational and clinical cancer research from MD Anderson experts. This special edition features presentations at the 2021 American Society of Hematology (ASH) Annual Meeting on innovative targeted therapies, new combination approaches, and novel…

Continue Reading MD Anderson research highlights 9 December

GRRDUser Manual [PDF] | Documents Community Sharing

* The preview only display some random pages of manuals. You can download full content via the form below. Microsoft Word Add-In for the GenePattern Reproducible Research Document July 2009 Introduction…………………………………………………………………………………………………………………. 3 About GenePattern…………………………………………………………………………………………………… 3 How GenePattern and the GRRD Add-In Work Together…………………………………………………4 Reproducibility of Document Interactions………………………………………………………………………4 Installing and Uninstalling…

Continue Reading GRRDUser Manual [PDF] | Documents Community Sharing

FDA clears IND application for CRISPR-edited T-cell receptor therapy to treat AML

September 17, 2021 1 min read ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . “ data-action=”subscribe”> Subscribe We were unable to process…

Continue Reading FDA clears IND application for CRISPR-edited T-cell receptor therapy to treat AML

Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Courtesy Intellia Therapeutics Intellia Therapeutics is celebrating another first today as the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for NTLA-5001, its first wholly-owned ex vivo CRISPR genome editing candidate. NTLA-5001 is being developed for the treatment of acute myeloid leukemia (AML). Intellia…

Continue Reading Intellia Therapeutics Set to Enter Clinic with First Solo Ex Vivo Candidate

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia | DNA RNA and Cells

Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia Details Category: DNA RNA and Cells Published on Thursday, 16 September 2021 17:52 Hits: 130 NTLA-5001 is Intellia’s first ex vivo candidate using its proprietary cell engineering…

Continue Reading Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia | DNA RNA and Cells

Paired-end reads reported without mates: how to play matchmaker?

Hi Everyone, I am currently looking at Acute Myeloid Leukemia (AML) paired-end WGS samples from the TARGET data ocg.cancer.gov/programs/target/target-methods#3241. A bioinformatician in our group remapped the samples from hg19 to hg38. Unfortunately, we do not have any copies of the hg19 version anymore. However, when I try to run anything…

Continue Reading Paired-end reads reported without mates: how to play matchmaker?

Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Stochastic Amplicon Ligation. DNA samples for oncology sequencing are typically extracted from FFPE tissues and can have average lengths of less than 500 nt due to accumulated chemical damage [18]. We developed the Stochastic Amplicon Ligation (SAL) method to enzymatically concatenate many short DNA molecules together to utilize the long-read…

Continue Reading Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection | Genome Biology

Cellectis Announces Participation in Five Investor

NEW YORK, Aug. 26, 2021 (News) — Cellectis S.A. (NASDAQ: CLLS – EURONEXT Progress: ALCLS) (the “Company”), a gene-modifying platform firm with scientific-stage immuno-oncology plans making use of allogeneic chimeric antigen receptor (Vehicle)-T cells and gene remedy courses for monogenic diseases, now declared that management plans to take part in…

Continue Reading Cellectis Announces Participation in Five Investor

How get Genetic Positions of SNPs?

How get Genetic Positions of SNPs? 0 I have some datasets related to different diseases like AML, etc. The data which I have include markers’ genotypes (AA, AB, BB) and some other information like chromosome number, physical position, strand,etc. For some reasons I need to have the genetic positions of…

Continue Reading How get Genetic Positions of SNPs?

Integrated bioinformatics analysis to identify abnormal CC

Introduction In recent years, the morbidity and mortality of colon cancer have increased rapidly, both being ranked fourth worldwide. Although surgery-based comprehensive treatments improve the prognosis of colon cancer, because of the lack of available means for early diagnosis, the mortality level remains high for patients with advanced-stage cancer. The…

Continue Reading Integrated bioinformatics analysis to identify abnormal CC

Bioconductor – SingscoreAMLMutations

DOI: 10.18129/B9.bioc.SingscoreAMLMutations     Using singscore to predict mutations in AML from transcriptomic signatures Bioconductor version: Release (3.13) This workflow package shows how transcriptomic signatures can be used to infer phenotypes. The workflow begins by showing how the TCGA AML transcriptomic data can be downloaded and processed using the TCGAbiolinks…

Continue Reading Bioconductor – SingscoreAMLMutations

ICA – Reconstruction Errors

ICA – Reconstruction Errors 0 Hello people! I am completely new to the topic of ML and Omics and at all in the bioinformatics field. To gather some knowledge I started to work through a book I found on the internet and there is the following task: “Produce a 10-component…

Continue Reading ICA – Reconstruction Errors